Advancing Knowledge. Enhancing Care.
Advancing Knowledge. Enhancing Care.

Psoriasis News

the latest news from ipc, industry and others

Blog

Displaying 1 to 10 of 88 Posts . Displaying 10 of Posts . Page of 9 . Go To Page: . Per Page: . . . View All Sort By: .

New corporate member

IPC is pleased to welcome Arcutis Biotherapeutics, Inc. as a Bronze Level Corporate Member!

Read More

Additional data added to the PsoProtect Registry

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes 1,369 cases.

Read More

New board members

Meet the three new key opinion leaders who have been elected to join our board.

Read More

New board officers

IPC's newly appointed appointed officers take their roles beginning January 1, 2022.

Read More

FDA approves Otezla® for treatment of plaque psoriasis

The FDA has approved Otezla® (apremilast) for the treatment of adult patients with plaque psoriasis.

Read More

FDA grants Priority Review for spesolimab

The FDA has granted priority review for spesolimab for the treatment of generalized pustular psoriasis flares.

Read More

European Commission approves SKYRIZI® for psoriatic arthritis in adults

The European Commission has approved SKYRIZI® for the treatment of active psoriatic arthritis in adults.

Read More

Focus on Psoriasis – A Report from the 2021 Virtual EADV Congress

The European Academy of Dermatology and Venerelogy 30th Annual Congress (EADV) was packed with science and clinical practice updates. You can download the full report or read a brief look at some of the highlights.

Read More

PsoProtect Registry Data Update

PsoProtect, a global registry for clinicians to report outcomes of COVID-19 in individuals with psoriasis, has updated their preliminary data and now includes the first 1,272 cases.

Read More

Update on spesolimab for generalized pustular psoriasis

The European Medicines Agency (EMA) has accepted to review Boehringer Ingelheim’s marketing authorization application (MAA) for spesolimab to treat flares in generalised pustular psoriasis (GPP).

Read More

Stay informed

Join the email list to receive the latest information on psoriasis meetings, manuscripts and research.
SUBSCRIBE

now available

COVID-19 Psoriasis Resource Center

Information from around the world on psoriasis and coronavirus to assist dermatologists and the patients they serve

explore now

 

We use cookies on this site to enhance your online experience. By continuing to use this site, you agree to accept cookies.
OK